Wellington Management Group LLP Raises Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Wellington Management Group LLP boosted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,671,157 shares of the company’s stock after purchasing an additional 419,329 shares during the quarter. Wellington Management Group LLP owned about 0.66% of Teva Pharmaceutical Industries worth $259,899,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Norges Bank bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $1,098,060,000. WCM Investment Management LLC increased its stake in Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after acquiring an additional 5,917,423 shares in the last quarter. Finally, Schroder Investment Management Group raised its holdings in shares of Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after acquiring an additional 5,370,253 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the sale, the executive vice president directly owned 65,621 shares in the company, valued at approximately $2,237,676.10. This represents a 61.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $36.45 on Monday. The stock has a market cap of $42.48 billion, a price-to-earnings ratio of 60.75, a price-to-earnings-growth ratio of 3.91 and a beta of 0.86. The firm has a 50-day moving average of $34.31 and a two-hundred day moving average of $33.19. Teva Pharmaceutical Industries Ltd. has a 1 year low of $17.94 and a 1 year high of $38.37. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion during the quarter. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent research reports. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 21st. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.22.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.